Search results for "Overall Survival"

showing 10 items of 87 documents

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

2019

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAA…

Male0301 basic medicinemedicine.medical_specialtySurvival rateCarcinoma HepatocellularCirrhosisSustained Virologic ResponsePrognosiHepatitis C virus (HCV) Hepatocellular carcinoma (HCC) Direct-acting antiviral (DAA) Overall survival Prognosis Survival rate Liver cirrhosisHepacivirusAntiviral AgentsGastroenterologyLiver cirrhosi03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEarly Hepatocellular CarcinomaOverall survivalProspective StudiesHepatocellular carcinoma (HCC)Propensity ScoreSurvival rateAgedAged 80 and overHepatologybusiness.industryLiver NeoplasmsHazard ratioDirect-acting antiviral (DAA)Hepatitis CHepatitis C virus (HCV)Middle Agedmedicine.diseasePrognosisHepatitis CDirect-acting antiviral (DAA); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Survival rate030104 developmental biologyHepatocellular carcinomaLiver cirrhosisFemale030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessViral hepatitisFollow-Up Studies
researchProduct

Transoral laser microsurgery for glottic cancer in the elderly: Efficacy and safety

2018

Background Data about the results of transoral laser microsurgery (TLM) in elderly patients are limited. Methods A retrospective study of 72 consecutive cases of glottic carcinoma (63 pT1 and 9 pT2 cases) in elderly patients (≥70 years old, mean 76 years) treated with TLM was made. A systematic review of the literature was performed. Results Six patients (8%) had postoperative complications, but no treatment-related deaths were observed. Local recurrences occurred in 12 patients (16.5%): nine with pT1 (14%) and three with pT2 (33%) tumors. Five-year disease-specific survival (DSS), overall survival, and laryngectomy-free survival were 95%, 68%, and 88%, respectively. The literature review i…

MaleGlottisMicrosurgerymedicine.medical_specialtycomplicationsLaryngectomyTreatment resultselderly03 medical and health sciencesPostoperative Complications0302 clinical medicineOverall survivalHumansMedicineEffective treatmentTransoral laser microsurgerycomplications; elderly; laryngeal cancer; transoral laser microsurgery; Otorhinolaryngology2734 Pathology and Forensic Medicine030223 otorhinolaryngologytransoral laser microsurgeryLaryngeal NeoplasmsAgedRetrospective Studiesbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineBackground dataAge FactorsRetrospective cohort studySurgeryTreatment OutcomeOtorhinolaryngologyGlottic cancer030220 oncology & carcinogenesisCarcinoma Squamous Celllaryngeal cancerFemaleLaser TherapybusinessHead & Neck
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

2020

Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.430 consecutive patients treated with Radium-223 alone or in combination with BHA, affe…

MaleRadium-223Oncologymedicine.medical_specialtyRadium-223 dichlorideRadium-223 dichloride; bone health agents; mCRPC; overall survival; prostate canceroverall survivalBone healthBone and Bones030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineBone MarrowInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingRadium-223 DichlorideNeoplasm MetastasisAgedL-Lactate DehydrogenaseRadiological and Ultrasound Technologybusiness.industrymCRPCAlkaline Phosphataseprostate cancermedicine.diseaseSurvival AnalysisRANK Ligand InhibitorProstatic Neoplasms Castration-ResistantDenosumabMulticenter studybone health agents030220 oncology & carcinogenesisSettore SECS-S/01businessRadiummedicine.drugInternational Journal of Radiation Biology
researchProduct

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

2018

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versu…

MaleTemsirolimusCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-CellGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols80 and overClinical endpointmedia_commonAged 80 and overHazard ratioHematologyMiddle AgedPrognosisTemsirolimusSurvival RateLocalOncology030220 oncology & carcinogenesisInjections IntravenousRefractory Mantle Cell LymphomaFemaleIntravenousmedicine.drugsafetymedicine.medical_specialtyoverall survivalmantle cell lymphomaAntineoplastic AgentsDrug Administration ScheduleInjections03 medical and health sciencesRefractoryInternal medicinemedicineHumansmedia_common.cataloged_instanceProgression-free survivalEuropean unionAgedSirolimusSalvage Therapybusiness.industryMantle-Cellmedicine.diseaseSurgeryNeoplasm RecurrenceDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusinessprogression-free survivalFollow-Up Studies030215 immunology
researchProduct

First hospital contact via the Emergency Department is an independent predictor of overall survival and disease-free survival in patients with colore…

2019

espanolObjeto: el objetivo del presente estudio es examinar la asociacion entre el tipo de admision hospitalaria, la supervivencia y las caracteristicas patologicas de una amplia poblacion de pacientes con cancer colorrectal. Metodos: realizamos un estudio en 1.079 pacientes diagnosticados en el Hospital Costa del Sol de Marbella con cancer colorrectal y evaluamos la relacion entre su tasa de supervivencia y la via por la que realizaron el primer contacto con el hospital (admision programada o de urgencias). Las variables incluidas en nuestro estudio fueron las siguientes: edad, genero, localizacion del tumor, estadio patologico, grado de diferenciacion, quimioterapia previa a la cirugia y …

Malemedicine.medical_specialtyDisease free survivalSurvivalColorectal cancerAdmissionKaplan-Meier EstimateColon tumorsIndependent predictorDisease-Free SurvivalPatient AdmissionSex FactorsmedicineOverall survivalHumansIn patientAgedRetrospective StudiesGynecologyRectal Neoplasmsbusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineEmergency departmentmedicine.diseasePrognosisColorectal cancerSurvival RateSpainColonic NeoplasmsRegression AnalysisFemaleEmergency Service HospitalbusinessEmergency service
researchProduct

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

2014

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …

Malemedicine.medical_specialtyPediatricsCarcinoma HepatocellularTime FactorsHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIADiseaseGastroenterologyBiasInternal medicineOverall survivalmedicineHumansEarly Detection of CancerAgedEstimationSurveillanceHepatologybusiness.industryLiver Neoplasmsmedicine.diseasedigestive system diseasesLead time biasCirrhosisHepatocellular carcinomaFemalebusinessLead-time biasFollow-Up Studies
researchProduct

Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study

2019

Abstract Background For complete removal of intrahepatic cholangiocarcinoma (ICC), extended resection is often necessary. Information on the influence of visceral or vascular extension, extended resection, or postoperative morbidity on survival is scarce. The aim of this study was to show the impact of an aggressive surgical attitude on morbidity, mortality, and long-term outcome. Materials and methods All explorations at a high volume tertiary center between January 2008 and June 2018 with histological proof of ICC were included in this retrospective cohort study. The primary outcome was the extent of resection, secondary outcomes were postoperative morbidity, and their influence on overal…

Malemedicine.medical_specialtySingle CenterResectionCholangiocarcinomaPrimary outcomeOverall survivalHepatectomyHumansMedicineIn patientPostoperative PeriodIntrahepatic CholangiocarcinomaAgedRetrospective Studiesbusiness.industryLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurvival AnalysisSurgeryBile Ducts IntrahepaticTreatment OutcomeBile Duct NeoplasmsFemaleSurgeryMorbiditybusinessCohort studyInternational Journal of Surgery
researchProduct

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian M…

2020

Abstract Background We investigated, in a real-life setting, the prognostic relevance of previous primary treatment (radical prostatectomy [RP] or external beam radiotherapy [EBRT]) on overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Materials and Methods In the present multicenter retrospective study, we enrolled 275 consecutive patients. The demographic and clinical data and mCRPC characteristics were recorded and evaluated at baseline and at the end of treatment or progression. 223Ra was administered according to the current label authorization until disease progression or unacceptable toxicity. We divided the who…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentoverall survivalBrachytherapy030232 urology & nephrologyUrology223-ra03 medical and health sciencesProstate cancer0302 clinical medicineAblative casemedicineHumansExternal beam radiotherapyradiotherapyAgedRetrospective StudiesAged 80 and overProstatectomyRadioisotopesbusiness.industryProstatectomyRetrospective cohort studymCRPCMiddle AgedProtective Factorsmedicine.diseasePrognosisCombined Modality TherapyRadiation therapySurvival RateProstatic Neoplasms Castration-ResistantOncologyMulticenter study223-ra; mCRPC; prostatectomy; radiotherapy; overall survivalItaly030220 oncology & carcinogenesisCohortDisease ProgressionbusinessSettore SECS-S/01Follow-Up StudiesRadium
researchProduct

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct